SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
Tag: hfpef
Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial
1. In this randomized, controlled trial, for patients with heart failure and left ventricular ejection fraction higher than 40%, sacubitril/valsartan ...
Substantial prevalence of transthyretin amyloid cardiomyopathy present in patients with heart failure with preserved ejection fraction
1. Transthyretin amyloid cardiomyopathy was present in a substantial number of patients with heart failure with preserved ejection fraction and ...
Relative risk of heart failure from traditional risk factors is greater in younger than in older adults
1. Hypertension, diabetes, smoking, atrial fibrillation, and previous myocardial infarction were associated with a higher risk of incident heart failure ...
Spironolactone use associated with improved outcomes for patients with HFpEF and resistant hypertension
1. Among patients with HFpEF and resistant hypertension, administration of spironolactone was associated with a reduced risk of composite cardiovascular ...
